Enhancement and Availability

Formulation Models

Predictive Formulation: Can Modeling Reduce Empirical Development?

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Spray-Dried Dispersions vs. Nanocrystals: Which Is Better for Solubility Enhancement?

Nice Insight

Viral Vectors

Gene Therapy Manufacturing After the Capacity Boom

David Alvaro, Ph.D.

Pharma's Almanac

New Technology

What are the key bottlenecks preventing rapid adoption of novel technologies?

Pharma's Almanac

Heme-Onc

Therapeutic and Diagnostic Advances Benefiting Patients with Hematologic Malignancies

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Pathfinder

Micronization vs. Nanomilling vs. Amorphous Solid Dispersions: Which Is Better for Poorly Soluble Drugs?

Nice Insight

Heme-Onc

The Next Generation of Targeted Therapies in Hematologic Malignancies

DDC Development

Building Better Combination Products by Engaging Device Development Earlier

Loganathan S.

OneSource Specialty Pharma

Allogeneic CAR-T

Can Allogeneic Cell Therapy Solve the CAR-T Access Problem?

Pharma's Almanac

BsAbs in Oncology

Bispecific Antibodies Move Into the Heme-Onc Mainstream

David Alvaro, Ph.D.

Pharma's Almanac

Child Formulation

The Pediatric Formulation Gap

Pharma's Almanac